Amgen Tells Full Fed. Circ. Antibody IP Ax Dooms Biologics
Amgen has asked the full Federal Circuit to review a panel's determination that two patents covering its cholesterol medication Repatha are too broad to be enabled, a decision it said created...To view the full article, register now.
Already a subscriber? Click here to view full article